Clinical trials: Manic Disorder
Bipolar I Disorder, Mania
A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features
1) To evaluate the efficacy and safety of cariprazine at a target dose of 3.0 mg/day compared with placebo in prevention of relapse in patients with bipolar I disorder whose current episode (i.e.
- Conditions
- Bipolar I Disorder, Mania, Depression
- Trial name
- NCT03573297
- Testing
- Cariprazine
- Where
- 108 sites in United States, Bulgaria and 9 more
- Volunteers
- 901 people
- Sponsor
- AbbVie
Bipolar Disorder
Psychoeducation Versus Cognitive-Behavioral Therapy in Bipolar Disorder
To examine the impact of cognitive-behavioural therapy on both the episodic and functional outcome of bipolar disorder, in combination with pharmacotherapy. Primary Hypothesis is twofold: 1.
- Trial name
- NCT00188838
- Testing
- Psychoeduction, Cognitive-Behavioral Therapy
- Where
- 6 sites in Canada
- Volunteers
- 210 people
- Sponsor
- University Health Network, Toronto
Bipolar Disorder (BD)
Anticipating Depressive and Manic Episodes in Bipolar Disorders Using Vocal Biomarkers
Bipolar disorder (BD) is a chronic, cyclical mental illness affecting over 1% of the global population. It is characterized by alternating episodes of elevated mood and energy (mania or hypomania) and episodes of decreased mood…
- Trial name
- SPEECHBIPO (NCT07298278)
- Testing
- Voice interviews and questionnaires carried out via the CALLYOPE application, Sleep measurements using an under-mattress sensor, Smartwatch for measuring activity, sleep, and skin temperature
- Volunteers
- 170 people
- Sponsor
- Centre Hospitalier St Anne
Bipolar Disorder
Clinical Trial of Mifepristone for Bipolar Depression
Bipolar Depression is a severe illness with high rates of psychiatric comorbidity and increased mortality related to suicide and medical illness.
- Trial name
- NCT00043654
- Testing
- Mifepristone
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia, Schizoaffective Disorder
A Definitive Estrogen Patch Study (ADEPT)
OBJECTIVE: To test the use of adjunctive estrogen in a 8 week, three-arm, double-blind, placebo-controlled study in the treatment of psychotic symptoms in women with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder(Not in Manic Phase)
- Trial name
- NCT00357006
- Testing
- Estradiol
- Where
- Australia
- Volunteers
- 180 people
- Sponsor
- The Alfred
Mania, Sleep
Ottawa Sunglasses at Night for Mania Study
Mania is a serious condition. Symptoms of mania include decreased sleep, increased energy, changes in mood, thinking, and behavior.
- Conditions
- Mania, Sleep, Bipolar Disorder
- Trial name
- OSAN (NCT05206747)
- Testing
- Blue-blocking glasses, Lightly-tinted glasses
- Where
- 2 sites in Canada
- Volunteers
- 42 people
- Sponsor
- Ottawa Hospital Research Institute
Bipolar Disorder, Schizophrenia
Treatment of Mania Symptoms With Drug Therapy
This study will determine the effectiveness of three different drug therapies in treating the symptoms of mania.
- Trial name
- NCT00183443
- Testing
- Divalproex-extended release (DVP-ER), Lithium, Quetiapine
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Palo Alto Veterans Institute for Research
Pediatric Bipolar Disorder
Invega (Paliperidone) for the Treatment of Mania in Children and Adolescents Ages 6-17 With Bipolar Disorder
This will be an 8-week open-label trial, using daily doses of paliperidone (Invega) in the treatment of children and adolescents who meet DSM-IV criteria of Bipolar I, Bipolar II, or Bipolar Spectrum Disorder.
- Trial name
- NCT00592358
- Testing
- paliperidone
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Massachusetts General Hospital
Bipolar Disorder, Manic
Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania
This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with…
- Trial name
- NCT06462586
- Testing
- Lumateperone
- Where
- 42 sites in United States, Bulgaria and 3 more
- Volunteers
- 354 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Bipolar Disorder
Optimal Length of Treatment Continuation With Olanzapine After Remission of Manic or Mixed Episode
This is a randomized, parallel, open-label study of patients who have responded to treatment in the acute phase of their manic or mixed episode, with or without psychotic symptoms, with olanzapine in mono or co-therapy, and who…
- Trial name
- NCT00191997
- Testing
- Olanzapine
- Where
- 11 sites in Spain
- Volunteers
- 180 people
- Sponsor
- Eli Lilly and Company
Major Depression, Bipolar Disorder
Longitudinal Study of People Presenting for First Treatment of a Mood Disorder
The goal of this project is to study the course and outcome of illness in individuals who present with a first episode of depression or mania, or who have a recurrent disorder but have never received treatment.
- Trial name
- NCT01529905
- Where
- Canada
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- McMaster University
Depression - Major Depressive Disorder, Schizophenia Disorder
A Novel Blood Test as a Biomarker in Mental Health
This longitudinal, observational study aims to assess whether the characteristics of a novel blood peripheral biomarker can serve as indicators for depression and schizophrenia in patients at the Royal Columbian Hospital…
- Conditions
- Depression - Major Depressive Disorder, Schizophenia Disorder, Psychosis, Mania (Neurotic)
- Trial name
- LEADING-MH (NCT06856161)
- Where
- Canada
- Volunteers
- 500 people
- Sponsor
- Fraser Health
Bipolar Disorder
Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)
The purpose of this study is to assess the safety and tolerability of ziprasidone during a long-term open label study in children and adolescents (ages 10-17) with Bipolar I Disorder (Manic or Mixed).
- Trial name
- NCT01124877
- Testing
- ziprasidone oral capsules
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Bipolar Disorder
40 Week Trial to Study the Safety of Asenapine When Added to Lithium or Valproate in the Treatment of Bipolar Disorder (A7501009)(P05786)
The primary objective of this trial was to characterize the long-term (up to 40 weeks) safety and tolerability of asenapine in bipolar I disorder subjects who had not completely responded to continuing treatment with lithium or…
- Trial name
- NCT00145509
- Testing
- Asenapine
- Volunteers
- 77 people
- Sponsor
- Organon and Co
Schizophrenia
Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia
Part 1 of the study will assess the enhancement of task-related brain activation (BOLD response) in key brain areas in schizophrenia during the performance of working memory, episodic memory and visual activation tasks as…
- Trial name
- NCT00825539
- Testing
- AQW051
- Where
- 7 sites in United States
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
Bipolar Disorders, Manic Episode
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder
The purpose of the study is to assess the effectiveness and safety of risperidone (an antipsychotic medication) versus placebo during 3 weeks of treatment of mania in patients with Bipolar I Disorder who are suffering a manic…
- Trial name
- NCT00257075
- Testing
- Risperidone, oral tablets
- Volunteers
- 267 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Major Depressive Disorder
Lithium Versus Paroxetine in Major Depression
This study is being done to look at how well people respond to two different drug treatments for depression. Clinically, people can respond differently to different treatments for reasons which are not always clear.
- Trial name
- NCT01416220
- Testing
- Lithium, Paroxetine
- Where
- Canada
- Sponsor
- Nova Scotia Health Authority
Bipolar Disorder
DB/Maintenance of Equetro (Carbamazepine) in Children With Acute Manic or Mixed Bipolar 1 Disorder
A phase 4 unequal randomization, double blind study to evaluate the dose tolerance and safety of extended release Equetro (carbamazepine) versus placebo followed by an Open label and long term maintenance treatment in children…
- Trial name
- NCT02623504
- Testing
- Carbamazepine
- Where
- 4 sites in United States
- Volunteers
- 17 people
- Sponsor
- Validus Pharmaceuticals
Bipolar I Disorder
An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder
This extension study is designed to investigate the long-term safety and tolerability of licarbazepine 750-2000 mg/d over 52 weeks in patients who completed the 6-week double-blind study CLIC477D2302.
- Trial name
- NCT00238485
- Testing
- Licarbazepine
- Volunteers
- 251 people
- Sponsor
- Novartis
Psychosis, Mania
Combining mHealth and Nurse-delivered Care to Improve the Outcomes of People With Serious Mental Illness in West Africa
In West Africa, most people with serious mental illness receive care from traditional or faith healers at prayer camps. The stepped-wedge cluster randomized trial aims to evaluate the effectiveness of a dual-pronged intervention…
- Conditions
- Psychosis, Mania, Depression
- Trial name
- NCT05703711
- Testing
- mHealer
- Where
- Ghana
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- University of Washington